Stat Strip

• AI platforms analyzed: Gemini-led extraction dataset
• Tracked brands: 10 major ED / telehealth competitors
• High-intent observations: 21 pricing and evaluation prompts
• Core commercial battleground: pricing, affordability, and subscription evaluation

Answer Capsule

The ED treatment category is becoming increasingly shaped by AI-assisted pricing and affordability conversations rather than generic “best ED pill” discovery alone. Current signals suggest that Ro, Sesame, and BlueChew are disproportionately surfacing inside AI-generated pricing and cost-evaluation answers, while several recognized telehealth brands appear commercially absent despite strong market awareness. The strongest category signal is not who exists in AI answers — it is who consistently appears during high-intent cost and evaluation moments.

Executive Summary

The current AI discovery pattern inside the ED treatment market points to a narrowing recommendation and reference layer concentrated around a small set of telehealth-native brands.

The most commercially meaningful prompts in this dataset were not broad awareness queries. They were highly transactional evaluation prompts:

• “How much does BlueChew actually cost?”
• “How much does one BlueChew cost?”
• “How much does Ro cost?”
• “How much does Ro Sparks cost per month?”

These are not casual informational searches. They are buyer-decision moments.

Across the observed prompt set, Ro appeared most frequently in AI-generated pricing discussions, followed by Sesame and BlueChew. Hims — despite being one of the most recognized direct-to-consumer health brands in the category — showed effectively zero meaningful visibility inside this specific pricing-oriented AI prompt environment.

That distinction matters.

A brand can still dominate traditional awareness channels and still fail to become part of AI-assisted commercial evaluation.

The strongest category signal is not raw visibility. It is whether AI systems advance a company into the shortlist during buyer-intent moments.

Right now, the ED category appears increasingly driven by:

• affordability framing,
• subscription transparency,
• medication comparison logic,
• and telehealth pricing explainers.

This creates a structurally different discovery environment than traditional SEO.

The AI Discovery Shift in ED Treatment

Historically, the ED treatment market was dominated by:

• pharmaceutical awareness,
• search-engine rankings,
• aggressive paid acquisition,
• and direct-response advertising.

AI discovery changes the mechanism entirely.

Instead of users clicking through ten search results, AI systems increasingly synthesize:

• pricing summaries,
• brand comparisons,
• subscription explanations,
• medication distinctions,
• and affordability guidance directly inside answers.

That compresses shortlist formation.

In practice, this means AI systems are increasingly deciding:

• which brands are discussed,
• which companies feel credible,
• which pricing structures appear understandable,
• and which products become recommendation-adjacent.

The shift especially favors companies with:

• simple pricing narratives,
• strong structured informational content,
• recognizable product framing,
• and heavy participation in comparison-oriented consumer discussions.

This appears to be one reason Ro and BlueChew surfaced repeatedly inside the observed pricing cluster. Their products are comparatively easy for AI systems to summarize:

• monthly plans,
• subscription structures,
• dosage tiers,
• medication breakdowns,
• and telehealth workflows.

Complexity is becoming a disadvantage.

Directional Category Leaders

Ro

Ro currently appears to hold the strongest pricing-cluster presence inside this dataset.

The brand surfaced repeatedly across:

• weight-loss pricing comparisons,
• medication cost explainers,
• telehealth affordability prompts,
• and monthly subscription evaluation questions.

Importantly, Ro’s visibility was not necessarily recommendation-driven. Most appearances were neutral informational framing rather than explicit endorsement.

But repeated neutral presence during evaluation moments still matters commercially.

A brand that repeatedly appears during pricing evaluation can become cognitively dominant even without overt recommendation language.

Current directional framing:

• Leader
• Strong pricing visibility
• High comparison participation
• Consistent evaluation-layer presence

Sesame

Sesame appears to benefit from broad telehealth affordability framing.

The company surfaced repeatedly in prompts involving:

• telehealth visit costs,
• low-cost healthcare access,
• Costco-linked healthcare programs,
• and generalized pricing explainers.

This suggests Sesame may currently benefit from a wider “affordable healthcare marketplace” narrative rather than a narrowly ED-focused positioning layer.

Current directional framing:

• Strong option
• Affordable-care association
• Broad telehealth visibility
• Marketplace positioning advantage

BlueChew

BlueChew appears unusually concentrated around direct ED affordability prompts.

The strongest observed commercial-intent prompts included:

• “How much does BlueChew actually cost?”
• “How much does one BlueChew cost?”
• “How much does BlueChew cost?”

These queries carried some of the largest modeled demand pools in the dataset.

That matters because pricing intent is often downstream from awareness. These users are already evaluating purchase feasibility.

BlueChew’s AI visibility currently appears tightly connected to:

• subscription simplicity,
• dosage-plan clarity,
• and highly recognizable product framing.

Current directional framing:

• Specialist option
• Strong ED-specific pricing visibility
• Subscription-led commercial positioning
• Concentrated evaluation-layer presence

The Buying Moments That Now Decide the Category

The dataset suggests that pricing and affordability prompts are becoming some of the most commercially important AI discovery zones in ED treatment.

Several themes repeatedly emerged:

1. Monthly Cost Evaluation

Examples:

• “How much does Ro Sparks cost per month?”
• “How much does BlueChew actually cost?”

These prompts signal late-stage consideration behavior.

The buyer is no longer asking:

“What is ED treatment?”

They are asking:

“Can I justify this recurring expense?”

That is a much higher commercial-intent environment.

2. Subscription Transparency

AI systems repeatedly summarized:

• monthly plans,
• dosage tiers,
• recurring subscriptions,
• and bundled care models.

Brands with simple subscription narratives appear easier for AI systems to operationalize.

3. Telehealth Legitimacy

Prompts around:

• online doctor visit costs,
• telehealth affordability,
• and marketplace healthcare models

suggest AI systems increasingly frame telehealth brands as infrastructure providers rather than just medication vendors.

That changes competitive dynamics.

The category is drifting from:
“Which ED pill is best?”
toward:
“Which healthcare platform feels easiest, cheapest, and safest to use?”

4. Affordability and Access

The strongest demand clusters frequently involved:

• cheap access,
• monthly affordability,
• insurance avoidance,
• and low-friction healthcare acquisition.

This creates an environment where pricing clarity becomes part of discoverability itself.

Why Recommendation Power Is Concentrating

One of the clearest signals from this benchmark is that recommendation power appears increasingly concentrated around brands with highly extractable informational structures.

AI systems favor content that is:

• repetitive,
• structured,
• easy to summarize,
• and comparison-friendly.

This especially advantages:

• subscription products,
• telehealth workflows,
• tiered pricing structures,
• and standardized medication explanations.

The category also appears highly dependent on:

• pricing explainers,
• healthcare marketplace framing,
• and simplified medication narratives.

In practical terms, AI systems are not behaving like search engines.

They are behaving more like synthesis engines.

That means the winning brands are often:

• easiest to explain,
• easiest to compare,
• easiest to summarize,
• and easiest to trust quickly.

This is a very different optimization environment than legacy SEO alone.

The Category’s Most Visible Warning Sign

The clearest warning sign in this dataset is the apparent disconnect between consumer brand awareness and AI evaluation visibility.

Hims is the most notable example.

Despite being one of the category’s largest and most recognizable direct-to-consumer health brands, Hims showed effectively no meaningful presence across the observed pricing and evaluation prompt set.

That does not necessarily mean Hims lacks broader AI visibility.

It does suggest something narrower and potentially more important:

The brand may not currently dominate the specific buyer-choice moments where AI-assisted commercial evaluation is occurring.

That distinction is critical.

A company can:

• appear in awareness conversations,
• still fail to appear in affordability evaluation,
• still fail to enter the pricing shortlist,
• and still lose downstream conversion consideration.

Commercially, absence during evaluation moments may matter more than broad informational presence.

That is the category’s strongest warning signal right now.

What This Means for the Category

Several directional implications are emerging.

AI discovery is compressing the shortlist.

Users increasingly receive:

• summarized pricing,
• condensed comparisons,
• simplified recommendations,
• and pre-filtered options directly inside AI answers.

That reduces exploratory browsing behavior.

Pricing clarity is becoming a discoverability asset.

Brands with:

• understandable subscriptions,
• transparent monthly costs,
• and clean medication structures

appear more retrievable inside AI-generated answers.

Telehealth positioning may matter more than pharmaceutical branding.

Several visible brands were surfaced less as “drug companies” and more as:

• care platforms,
• healthcare marketplaces,
• or subscription health services.

That reframes the competitive battlefield.

Presence alone is insufficient.

The category increasingly requires:

• recommendation eligibility,
• comparison inclusion,
• pricing-layer participation,
• and evaluation-stage visibility.

A brand can still be present in AI answers and still be commercially absent.

What This Public Benchmark Does Not Include

This public benchmark is intentionally directional and incomplete.

It does not include:

• full competitor threat profiles,
• prompt-level recovery maps,
• citation failure diagnostics,
• platform-by-platform ranking breakdowns,
• proprietary recommendation weighting,
• or company-specific revenue exposure modeling.

The paid Authority Index deep-dive expands into:

• competitive displacement analysis,
• AI recommendation gap mapping,
• citation architecture diagnostics,
• prompt-cluster recovery opportunities,
• and AI visibility remediation strategy.

Methodology and Disclaimers

This benchmark reflects a directional snapshot of AI-assisted discovery behavior within the ED treatment category during the May 2026 reporting window.

Observed data included:

• 21 extracted pricing and evaluation observations,
• telehealth and ED-treatment competitor tracking,
• Gemini-oriented extraction workflows,
• and high-intent prompt clustering focused primarily on pricing and affordability evaluation.

Important limitations:

• This is not a complete market census.
• Presence does not equal recommendation.
• Neutral mentions were separated from positive recommendation behavior.
• Some prompt clusters had limited platform coverage.
• Economics discussed are directional rather than attributable revenue claims.
• Competitive positioning should be interpreted as indicative rather than definitive.

The benchmark is designed to show how AI systems currently appear to structure category evaluation — not to provide absolute market-share measurements.

CTA

LLM Authority Index produces company-specific AI discovery audits showing:

• where brands appear inside AI answers,
• where competitors are being advanced instead,
• which prompt clusters matter most commercially,
• and which citation or entity gaps may be limiting recommendation visibility.

The full enterprise report includes:

• competitor threat mapping,
• prompt-level AI visibility diagnostics,
• citation architecture analysis,
• and recovery opportunity modeling tailored to a specific brand.